b-ONE Total Knee System

K180446 · B-One Ortho, Corp. · JWH · Oct 12, 2018 · Orthopedic

Device Facts

Record IDK180446
Device Nameb-ONE Total Knee System
ApplicantB-One Ortho, Corp.
Product CodeJWH · Orthopedic
Decision DateOct 12, 2018
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Intended Use

The b-ONE Total Knee System is intended for total knee arthroplasty due to the following conditions: Painful, disabling joint disease of the knee resulting from: noninflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis), rheumatoid arthritis or post -traumatic arthritis. Post-traumatic loss of knee joint configuration and function. Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability. Revision of previous unsuccessful knee replacement or other procedure. Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard fracture- management techniques. Additional indications for Posterior Stabilized (PS) and Posterior Stabilized Plus (PS+) components: Ligamentous instability requiring implant bearing surface geometries with increased constraint. Absent or nonfunctioning posterior cruciate ligament. Severe anteroposterior instability of the knee joint. The b-ONE Total Knee System is intended for implantation with bone cement only. b-ONE Total Knee System components are not intended for use with other knee systems.

Device Story

Modular artificial knee replacement system; replaces diseased knee joint to restore function. Components include symmetric femoral components (cast cobalt chrome), tibial baseplates (forged titanium alloy), tibial inserts (conventional UHMWPE with cobalt chrome locking wire), and patellar resurfacing buttons (conventional UHMWPE). System features posterior stabilized (PS) and PS+ options for increased constraint. Used by orthopedic surgeons in clinical/surgical settings for total knee arthroplasty. Implantation requires bone cement. System is non-interchangeable with other manufacturers' devices. Benefits include restoration of joint function and stability in patients with degenerative or traumatic knee conditions.

Clinical Evidence

Bench testing only. Studies included tibial baseplate fatigue, locking mechanism strength, tibial post fatigue, constraint testing, contact area/stress analysis, tibiofemoral range of motion, UHMWPE material characterization, bacterial endotoxin testing, shelf life studies, and biocompatibility.

Technological Characteristics

Modular knee system; materials: cast cobalt chrome (femoral), forged titanium alloy (tibial baseplate), conventional UHMWPE (inserts/patella). Posterior stabilized design with PS and PS+ constraint options. Fixation: bone cement only. Single-use, sterile. No software or electronic components.

Indications for Use

Indicated for patients requiring total knee arthroplasty due to painful, disabling joint disease (osteoarthritis, traumatic arthritis, avascular necrosis, rheumatoid arthritis), post-traumatic loss of function, moderate varus/valgus/flexion deformity, revision of failed knee replacement, or distal femur/proximal tibia fractures. PS/PS+ components indicated for ligamentous instability, absent posterior cruciate ligament, or severe anteroposterior instability.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ October 12, 2018 Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. b-One Ortho Corp. % Allison Gecik Regulatory Affairs Manager 3 Wing Drive Suite #259 Cedar Knolls, New Jersey 07929 Re: K180446 Trade/Device Name: b-ONE Total Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee Joint Patellofemorotibial Polymer Semi-Constrained Cemented Prosthesis Regulatory Class: Class II Product Code: JWH Dated: September 5, 2018 Received: September 6, 2018 Dear Allison Gecik: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's {1}------------------------------------------------ requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Peter G. Allen -S 2018.10.12 12:11:22 -04'00' - FOR Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K180446 Device Name b-ONE Total Knee System Indications for Use (Describe) The b-ONE Total Knee System is intended for total knee arthroplasty due to the following conditions: · Painful, disabling joint disease of the knee resulting from: noninflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis), rheumatoid arthritis or post -traumatic arthritis, · Post-traumatic loss of knee joint configuration and function. · Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability. · Revision of previous unsuccessful knee replacement or other procedure. - · Fracture of the distal femur and/or proximal tibia that cannot be standard fracture- management techniques. Additional indications for Posterior Stabilized (PS) and Posterior Stabilized Plus (PS+) components: - · Ligamentous instability requiring implant bearing surface geometries with increased constraint. - · Absent or nonfunctioning posterior cruciate ligament. - · Severe anteroposterior instability of the knee joint. The b-ONE Total Knee System is intended for implantation with bone cement only. b-ONE Total Knee System components are not intended for use with other knee systems. | Type of Use (Select one or both, as applicable) | |-------------------------------------------------| |-------------------------------------------------| | <span style="font-family: Arial;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |-----------------------------------------------------------------------------------------|-----------------------------------------------| |-----------------------------------------------------------------------------------------|-----------------------------------------------| #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ## TRADITIONAL 510(K) SUMMARY As required by 21 CFR 807.92 # Submitter Information: | Submitter's Name: | b-ONE Ortho, Corp. | | |------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------| | Address: | 3 Wing Drive<br>Suite 259<br>Cedar Knolls, NJ 07927 | | | Telephone: | 866-276-4538 | | | Contact Person: | Allison Gecik | | | Telephone: | 973-587-8431 | | | Date Prepared: | September 5, 2018 | | | Proprietary Name: | b-ONE Total Knee System | | | Classification: | Class II | | | Classification Panel: | Orthopedic | | | Common Name: | Total Knee Joint Replacement | | | Product Code(s): | JWH | | | | Classification Name(s): | Regulation<br>Number | | | Prosthesis, Knee, Patellofemorotibial, Semi-<br>Constrained, Cemented, Polymer/Metal Polymer knee<br>joint patellofemorotibial polymer/metal/polymer semi-<br>constrained cemented prosthesis | 888.3560 | | Legally Marketed<br>Predicate Devices to Which<br>Substantial Equivalence is<br>Claimed: | Stryker Triathlon Total Knee Replacement System, K031729, K070095 | | | Legally Marketed Reference<br>Devices Used to Support<br>Substantial Equivalence: | Stryker Scorpio NRG, K030978<br>Zimmer NexGen LPS, K960279<br>Zimmer NexGen Fluted Stemmed Tibial<br>Component, K963148<br>Depuy Attune PS, K111433<br>Omni Life Science Apex Knee System, K060192<br>Zimmer Persona, K121771<br>Zimmer NexGen All Poly Patella, K933785 | | {4}------------------------------------------------ ### Intended Use: The b-ONE Total Knee System is intended for total knee arthroplasty due to the following conditions: - Painful, disabling joint disease of the knee resulting from: noninflammatory degenerative joint ● disease (including osteoarthritis, traumatic arthritis, or avascular necrosis), rheumatoid arthritis or post -traumatic arthritis. - . Post-traumatic loss of knee joint configuration and function. - Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability. - . Revision of previous unsuccessful knee replacement or other procedure - Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard fracture-. management techniques. Additional indications for Posterior Stabilized (PS) and Posterior Stabilized Plus (PS+) components: - Ligamentous instability requiring implant bearing surface geometries with increased constraint. ● - Absent or nonfunctioning posterior cruciate ligament. ● - Severe anteroposterior instability of the knee joint ● The b-ONE Total Knee System is intended for implantation with bone cement only. b-ONE Total Knee System components are not intended for use with other knee systems. #### Device Description/Technological Characteristics: The b-ONE Total Knee System is a modular artificial knee replacement system comprised of symmetric cemented femoral components with optional femoral distal pegs, symmetric cemented tibial baseplate, symmetric tibial inserts with locking wires, symmetric patellar resurfacing button, and reusable surgical instruments. The therapeutic effect is replacement of the diseased joint with artificial components to restore joint function. The system is a posterior stabilized device type and includes two options for posterior stabilization, a PS and a PS+. The PS+ is designed with additional constraint when more stability is required. Compatibility of the system components is only claimed with the b-ONE Total Knee System. There is no allowed interchangeability with systems manufactured by other companies. The System includes left and right femoral components manufactured from cast cobalt chrome. The system includes 30 sizes. Sizes 1-10 are provided in right and left versions. Sizes 3-7 are provided in both standard and narrow configurations, with the narrow sizes having a relatively smaller aspect ratio of the medial-lateral to anterior-posterior widths when compared to the standard sizes. Optional modular distal pegs are included in the system. The system includes a Patella Component offered in seven sizes of variable diameter and thicknesses. The bone fixation surface incorporates three fixation pegs. The Patella Components are made from Conventional UHMWPE. The system includes Tibial Inserts which are offered in 40 sizes, size A/1-4 through HJ/7-10 with 8 thicknesses and 48 sizes for PS+ inserts, size A1-2+ through HJ/7-10+ with 8 thicknesses. The Tibial Inserts are made from Conventional UHMWPE. The Tibial Inserts are pre-assembled with a locking wire which is manufactured from Cobalt Chrome alloy. The system includes Tibial Baseplates offered in 9 sizes ranging from A-J. Tibial Baseplates are manufactured from forged titanium alloy. All system components are supplied sterile and are single use devices. {5}------------------------------------------------ ## Comparison of Technological Characteristics The design features and materials of the subject devices are substantially equivalent to those of the predicate devices. The b-ONE® Total Knee System and the predicate devices share the following characteristics: - Materials of construction - Manufacturing processes - Sizes offered - Product design for shape and macrostructures - Sterilization methods ● # Performance Data The following performance data were provided in support of the substantial equivalence determination. Non-Clinical Studies - Tibial Baseplate Fatigue ● - Locking Mechanism Strength ● - Tibial Post Fatigue - Constraint - Contact Area and Contact Stress ● - Tibiofemoral Range of Motion - Characterization of UHMWPE Insert Material ● - Bacterial Endotoxin Testing ● - Shelf Life Studies ● - Biocompatibility ## Conclusion The information provided above supports that the b-ONE Total Knee System is as safe and effective as the predicate devices with the same intended use. Some minor differences in design and technology exist between the subject and predicate devices, however applicable reference devices have been cited to support the conclusion that these differences do not raise any new questions of safety and effectiveness. The b-ONE Total Knee System is substantially equivalent to the predicate devices.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%